JP2025505644A - Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法 - Google Patents

Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法 Download PDF

Info

Publication number
JP2025505644A
JP2025505644A JP2024546422A JP2024546422A JP2025505644A JP 2025505644 A JP2025505644 A JP 2025505644A JP 2024546422 A JP2024546422 A JP 2024546422A JP 2024546422 A JP2024546422 A JP 2024546422A JP 2025505644 A JP2025505644 A JP 2025505644A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
independently selected
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505644A5 (cg-RX-API-DMAC7.html
Inventor
ティモシー ジェイ. センター,
サマンサ アングル,
マイケル エー. ブロドニー,
ジンロン ツァオ,
ジョン カム,
レスリー エー. デーキン,
エレナ ドルギフ,
ザッカリー ゲイル-デイ,
エレイン ビー. クルーガー,
スガンティニ ナンタクマール,
ジェシカ エイチ. オルセン,
アキラ ジェイ. シミズ,
スティーブン ディー. ストーン,
ハオシュアン ワン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2025505644A publication Critical patent/JP2025505644A/ja
Publication of JP2025505644A5 publication Critical patent/JP2025505644A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2024546422A 2022-02-08 2023-02-08 Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法 Pending JP2025505644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307876P 2022-02-08 2022-02-08
US63/307,876 2022-02-08
PCT/US2023/012578 WO2023154309A1 (en) 2022-02-08 2023-02-08 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
JP2025505644A true JP2025505644A (ja) 2025-02-28
JP2025505644A5 JP2025505644A5 (cg-RX-API-DMAC7.html) 2026-02-04

Family

ID=85685675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546422A Pending JP2025505644A (ja) 2022-02-08 2023-02-08 Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法

Country Status (7)

Country Link
US (1) US20250136612A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476228A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505644A (cg-RX-API-DMAC7.html)
CN (1) CN119013281A (cg-RX-API-DMAC7.html)
AU (1) AU2023218939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251124A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
HUP2200468A1 (hu) * 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
WO2023154309A1 (en) 2023-08-17
US20250136612A1 (en) 2025-05-01
CA3251124A1 (en) 2023-08-17
AU2023218939A1 (en) 2024-08-22
CN119013281A (zh) 2024-11-22
EP4476228A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
EP3806955B9 (en) Glp-1 receptor agonists and uses thereof
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
AU2023218939A1 (en) 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
TWI408135B (zh) 腎外髓質鉀通道抑制劑
AU2015266453C1 (en) Alk kinase inhibitor, and preparation method and use thereof
JP2024544060A (ja) Apol1のスピロ環式阻害剤およびこれを使用する方法
EP3080125A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
KR20220163429A (ko) 알파-1-항트립신 결핍증(aatd) 치료를 위한 알파-1-항트립신 조절제로서의 피롤로[2,3-f]인다졸 유도체 및 2,4,5,10-테트라아자트리시클로[7.3.0.03,7]도데카-1,3(7),5,8,11-펜타엔 유도체
CA3085353A1 (en) Quinazolinones as parp14 inhibitors
JP2025505647A (ja) Apol1阻害剤としての2-メチル-4’,5’-ジヒドロピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、およびそれを使用する方法
TW202329951A (zh) Apol1抑制劑及其使用方法
KR20230031990A (ko) 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
CA3181583A1 (en) Methods of use for pyrimidines as ferroportin inhibitors
OA21175A (en) Inhibitors of APOL1 and methods of using same.
EA040816B1 (ru) Агонисты рецептора glp-1 и их применение
WO2026076223A1 (en) Therapeutic compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260127